

# Novel neurosteroid drug candidates for the treatment of chemotherapy-induced painful neuropathies

Analogs of the natural non-toxic allopregnanolone to eradicate neuropathic pain with expected reduced side-effects

## KEYWORDS

Neuropathic pain  
Chemotherapy  
Cancer

## PATENTS

FR 1152390

23/03/2011

WO/2012/127176

filed on 23/03/12

National phases:

EP,US

## INVENTORS

Mensah G.

Meyer L.

Patte-Mensah C.

Taleb O.

Miesch M.

Geoffrey P.

Ressault B.

Strasbourg (France)

EA 4438 (Unistra)

UMR 7177 (Unistra-CNRS)



## TECHNOLOGY

- Based on Lab findings that the natural neurosteroid allopregnanolone, devoted on toxic side-effects in human, prevents and eradicates neuropathic symptoms evoked in rats by VINC and OXAL
- Identification of chemically optimized analogs that display a potent neuroprotective effect without proliferative action on human neuroblastoma SHSY5 cells

## APPLICATIONS

- Prevention and treatment of painful neuropathies
- In combination to cancer chemotherapy to prevent/suppress drug-evoked neuropathies

## INNOVATION ADVANTAGES

- Novel MOA preventing and repairing lesions responsible for neuropathic pain
- Expected to be safe, as analogs of the allopregnanolone

## DEVELOPMENT STATUS

- First *in vivo* POC in VINC-induced allodynia rat model
- Ongoing determination of PD parameters and non-toxic profile after oral administration in various animal models (prophylactic and therapeutic indication)

**Partnership** : Seeking partners to license the technology or to enter the co-conception program